Physiomics* 8.8p GBP8.6m (LON:PYC)
Yesterday afternoon the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, today announced it had entered into a partnership with Tabula Rasa HealthCare(R) (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety. Through this initiative, Physiomics’ personalised docetaxel model will be integrated into TRHC’s market-leading precision dosing solution, DoseMeRx(R). Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.
DP Poland SUSPENDED (LON:DPP)
Conditional share purchase agreement to acquire the entire issued share capital of Dominium S.A., a Polish pizza restaurant group Proposed Fundraising at 8p to raise gross proceeds of approximately GBP5.2 million of which GBP3.5m to be raised for the Company and approximately GBP1.7 million to be raised for the Seller . The Directors also believe that the combination of the two businesses will place the Company within the top three pizza chains in Poland in terms of stores and restaurants. It is expected that this improved scale will help the Company to achieve its objective of becoming a market leader in Poland, and it will help defend its current position from the growth noted amongst competitors.
Quadrise Fuels 2.075p GBP22.36m (LON:QFI)
The supplier of MSAR(R) emulsion technology and fuels, a low-cost, cleaner alternative to heavy fuel oil, provided an update on the expected conclusion of initial testing of bioMSAR(R) and announced that it has signed a Collaboration Agreement with Aquafuel Research Ltd, a British-based company specialising in renewable power innovation using conventional biofuels and glycerine. In accordance with the Agreement, Quadrise and Aquafuel will work together to jointly promote commercial glycerine supply, Aquafuel power solutions and bioMSAR(R) projects across various applications and regions.
The testing, first announced on 15 December 2020, is expected to be completed shortly with final report on the outcome expected in January 2021. bioMSAR(R) is a low carbon alternative to heavy fuel oil that combines renewable glycerine with MSAR(R) fuel technology to reduce CO2 emissions by 20-30%, as well as NOx and particulates.
Applied Graphene 40.5p GBP20.13m (LON:AGM)
The producer of speciality graphene nanoplatelet dispersions, announced that its customer, Halo Autocare Limited, a leading innovator in car care products, has launched Graphene Alloy Wheel Wax as part of its EZ Car Care range of products. This is the second graphene-enhanced wax polish product launched by Halo Autocare as part of its Graphene Innovation Programme, which uses AGM’s Genable(R) graphene dispersion technology. The microcrystalline wax-based polish is the result of the continued partnership and a rigorous testing programme delivered by Halo Autocare. This has produced a new product that delivers extended performance benefits, including improved thermal and chemical resistance to enhance coating durability further for demanding wheel and exhaust applications. The temperature resistance made possible through the new graphene nanoplatelet formulation helps with durability when alloy wheels heat up from consistent brake use. Combining these attributes with excellent barrier performance means that water spotting is also less likely to occur.
Touchstone Exploration 129p GBP269m (LON:TXP)
The National Gas Company of Trinidad and Tobago Limited (NGC) signed a natural gas supply agreement with Primera Oil and Gas Limited, a subsidiary of Canadian energy exploration company Touchstone Exploration on Friday 18th December 2020. Primera, acting on behalf of its Joint Venture partner Heritage Petroleum Company Limited, will supply gas from the Ortoire Block, initially from the Coho-1 field.
Paul Baay CEO of Touchstone commented: “This agreement provides a stable, multi-decade revenue stream for Touchstone to fully develop the world-class asset at Ortoire. This transforms the company from being an exploration company to one that is a full cycle energy provider. The structure of the agreement provides the shareholders of Touchstone with a predictable cash flow and earnings stream for years to come while minimising the capital required to maximise the resource.”
Zephyr Energy 0.825p GBP5.74m (LON:ZPHR)
The Board of Zephyr plans to spud the State 16-2 well today, well ahead of the Company’s year-end target date for the commencement of drilling. Over the last week, the Cyclone rig mobilised to the well site where it was subsequently assembled and tested. In addition, all ancillary services and service providers are now on site to support drilling operations.
The primary objectives of the well are to drill a mildly deviated well (8 degree maximum inclination) to an approximate true vertical depth (“TVD”) of 9,815 feet, so that the Company can acquire up to 100 feet of continuous core from the Cane Creek reservoir. The Company also plans to run a comprehensive well log suite across the entire Paradox Formation, which includes the primary Cane Creek reservoir target and at least five other potential reservoir zones, in order to gain additional insight into the potential of those secondary targets. Drilling operations are expected to take 30-40 days from this point forward, and the results from the analysis of the core and logs are expected within three months from the completion of drilling.
Scancell Holdings 13.375p GBP109m (LON:SCLP)
The developer of novel immunotherapies announced that they have selected their COVID-19 vaccine candidate, SN14, for further development and clinical trials. SN14 targets both the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain (RBD) of the spike (S) protein, and is based on a modification of Scancell’s ImmunoBody(R) DNA vaccine technology.
Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:
“We are very excited about our SN14 second generation COVID-19 vaccine which could have significant advantages over first generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long term protection.
Great Western Mining 0.197p GBP6.06m (LON:GWMO)
the mineral exploration and development company with gold, silver and copper assets in the USA, provided an update on operations at its Mineral Jackpot Properties ) in Mineral County, Nevada.
. Bulk material from the site is being processed through a gravity separation circuit and the pouring of first precious metal is on track to be achieved before year end
. .Pilot magnetometer survey completed over the northern part of the MJ area has highlighted existing known structures together with potential new linking structures and extensions to the south-east
The independent gold company with a portfolio of gold licences in Greenland, has been granted an increase to Mineral Exploration Licence 2020-36 “Anoritooq” by the Mineral Licence and Safety Authority. The amended licence covers 1,889 km2 in South Greenland and is considered prospective for gold, with similarities to AEX’s Vagar licence.
Pebble Group 111.5p GBP187m (LON:PEBB)
The provider of technology, services and products to the global promotional products industry announced that its Facilisgroup business has acquired software assets from CoreXpand, a US based software developer, for a total cash consideration of $5.3 million . The Acquisition will expand the services offered by Facilisgroup through its ecommerce platform via another robust technology solution, allowing for the easy development of e-stores ranging from online pop-up shops through to complex inventoried online stores for its existing and potential Partners (customers). The resultant product offering is expected to begin generating revenue by the end of H1 21 with a full suite of product capabilities expected to be in market in H1 22.
0203 764 2344
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.